Glycoprotein News and Research

RSS

Two-step regimen of experimental MERS vaccines show promise in mice

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV.

29 Jul 2015

Heidelberg University scientists gain new insight into cytotoxic effect of Ebola virus

In the course of basic research in membrane biochemistry scientists at Heidelberg University have gained new insight into the cytotoxic effect of the Ebola virus. Employing biochemical and cell biological methods they have shed light on the molecular relationships between the Ebola glycoprotein and its role in mediating cytotoxicity.

22 Jul 2015

New technique holds promise for improving glycoprotein-based pharmaceuticals

Researchers from the University of Copenhagen have discovered a way of improving biotech drugs. Better, cheaper and more effective drugs to combat cancer, arthritis and many other disorders.

21 Jul 2015

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.

22 Jun 2015

$Elotuzumab boosts response in relapsed, refractory multiple myeloma$

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.

4 Jun 2015

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Blood clots often form when lipid-rich plaques on the inner surface of arteries rupture and platelets aggregate at the site of injury. Cardiologists from Ludwig-Maximilians-Universitaet in Munich have now compared the effects of two new platelet aggregation inhibitors.

4 Jun 2015

New FAU study sheds light on link between inflammation and cancer

Although normal inflammation plays an important role in helping to fight off infections, there is mounting evidence that chronic inflammation is linked to increased risk of tumor development. A new study conducted by researchers in the Charles E. Schmidt College of Medicine at Florida Atlantic University is helping to shed light on the important link between inflammation and cancer, and how pre-existing inflammation may aid in the metastatic process.

3 Jun 2015

Ariana Pharma joins the GastricGlycoExplorer consortium

This collaboration is carried out within the GastricGlycoExplorer consortium, a European Commission funded project. The consortium aims at discovering and developing new diagnostic signatures by characterizing the sugars that are attached to the surface of gastric tissue. "Glycomics" provides a systematic approach for studying sugars that are naturally present on cell surfaces and its application may lead to determine early markers of gastric cancer.

2 Jun 2015

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once for long-lasting immunoprotection.

2 Apr 2015

Wyatt Technology’s CG-MALS system enables characterization of complex protein-protein interactions

Study published in Nature outlines use of Wyatt’s Calypso II system to confirm the stoichiometry of αSNAP-SNARE complex

From Waters | Wyatt Technology 26 Mar 2015

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

23 Mar 2015

Scientists design a promising vaccine for herpes viruses

Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine.

9 Mar 2015

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide.

9 Mar 2015

Researchers study safety, effectiveness of experimental Ebola vaccine following high-risk exposure

A physician who received an experimental Ebola vaccine after experiencing a needle stick while working in an Ebola treatment unit in Sierra Leone did not develop Ebola virus infection, and there was strong Ebola-specific immune responses after the vaccination, although because of its limited use to date, the effectiveness and safety of the vaccine is not certain, according to a study appearing in JAMA.

6 Mar 2015

TSRI researchers show how ABC transporters cause multidrug resistance

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy treatment.

3 Mar 2015

TSRI scientists show how to target weak spots of Marburg virus with future treatments

Marburg virus is Ebola's deadly cousin. The virus is up to 90 percent lethal—and doctors are desperate for tools to fight it.

27 Feb 2015

Study leads to discovery of rare genetic disorder

Recently, a grassroots effort initiated by families and clinicians led to the discovery of a human genetic disorder with severe consequences that is linked to a mutation in the human NGLY1 gene. In a big step towards understanding the effects of this mutation, research by scientists at the RIKEN-Max Planck Joint Research Center in Japan implicates the enzyme ENGase as the factor responsible for deficient protein degradation that occurs in the absence of mouse Ngly1 gene expression.

19 Jan 2015

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

8 Jan 2015

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

High speed, high resolution glycan mapping now achievable for mAb characterization

The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern. Recombinant monoclonal antibody therapeutics (mAbs) represent the largest group of therapeutic proteins the analysis of the glycan pattern is therefore an essential part of the mAb characterization process.

19 Dec 2014